Immunocore Holdings (IMCR) Revenue (2021 - 2026)

Immunocore Holdings has reported Revenue for 6 years, with the latest figure at $106.7 million in Q1 2026.

• Quarterly Revenue rose 13.63% year-over-year to $106.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $412.8 million (up 23.75% YoY) and the FY2025 annual result came in at $400.0 million, up 28.95% from the prior year.
• Revenue grew to $106.7 million in Q1 2026 per IMCR's latest filing, from $104.5 million in the prior quarter.
• Over five years, Revenue peaked at $106.7 million in Q1 2026 and troughed at $40.3 million in Q2 2022.
• A 5-year average of $75.7 million and a median of $73.0 million in 2024 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2026: Revenue surged 534.3% in 2022, then advanced 13.63% in 2026.
• Over 5 years, Revenue stood at $56.4 million in 2022, then advanced by 24.46% to $70.2 million in 2023, then advanced by 19.8% to $84.1 million in 2024, then grew by 24.3% to $104.5 million in 2025, then climbed by 2.1% to $106.7 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $106.7 million, $104.5 million, and $103.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.